1. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib
    Ashley L. Cole et al, 2020, JCO Oncology Practice CrossRef
  2. Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
    Takashi Hamada et al, 2018, Clinical Drug Investigation CrossRef
  3. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients
    Philippe Rousselot et al, 2021, British Journal of Haematology CrossRef
  4. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
    Nuno Cerveira et al, 2018, BMC Cancer CrossRef
  5. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients
    Yoshimichi Koutake et al, 2020, International Journal of Hematology CrossRef
  6. The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group
    Noriyoshi Iriyama et al, 2018, Internal Medicine CrossRef
  7. A 68-Year-Old Man With Chronic Myelogenous Leukemia and a Large Unilateral Pleural Effusion
    Adam Alter et al, 2018, Chest CrossRef